Spotlight
Doctors are leaving the NHS for tech startups – that’s not a bad thing | Dr Molly Gilmartin on LBC
AlbionVC Investment Director, Dr Molly Gilmartin shares on LBC why more clinicians are moving into healthtech
Deep Tech Spinouts: Inside AlbionVC’s Decade-Long Partnership with UCL | Dave Grimm
AlbionVC Partner Dave Grimm shares how a decade-long partnership with UCL is rewriting the rules for academic entrepreneurship
Can AI data pains lead to photonics business opportunities? | BI Foresight
AlbionVC partner Dave Grimm on why now is the time for photonics chips to shine
AlbionVC: London still outpaces Paris in tech | UKTN
Ed Lascelles, AlbionVC Partner shares insights on the State of European Tech: Why London Still Leads
Unlock the Future: AI Breakfast with AlbionVC, Humanloop & Google
We recently hosted an exclusive breakfast exploring the everchanging opportunities in the field of AI and LLMs
Startups Magazine | Bigtech won’t ever disrupt the NHS, but it will cause local ripples
Spotlight on AlbionVC’s European Healthtech Market Map in Startups Magazine
Bloomberg | 25 European startups that could change the world
Quantexa listed among the 25 European startups that could change the world
VCs Are Eyeing U.K. “Compute” Spinouts – Here’s Why? in Forbes
David Grimm, Partner AlbionVC chatted to Forbes about the opportunities and lessons learnt on backing Compute university spinouts
11 future of compute startups to watch, according to VCs | Sifted
David Grimm, Partner shared with Sifted two outstanding companies to watch
UK Innovation Update Report from HSBC Innovation Banking & Dealroom
Ed Lascelles, Partner, comments on the overview of Q1 2025 Venture Capital funding landscape
Citadel Securities Pitches Banks on Handling Their Bond Trades
Citadel Securities is enlisting a third-party firm, TransFICC, that will install its technology at banks and brokerages while sparing them the cost to connect.
Universities should not be greedy with technology spin-offs | FT
Dave Grimm, Partner at AlbionVC, chats to John Gapper, Financial Times, on the opportunities that commercialising research presents, on the back of our very successful partnership with UCL.